Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling
- 26 May 2026
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 368, 152719
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2022YFA1303700)
- ShanghaiTech University
- Ministry of Science and Technology of the People's Republic of China
This publication has 27 references indexed in Scilit:
- Development of a penetratin-conjugated stapled peptide that inhibits Wnt/β-catenin signalingBioorganic & Medicinal Chemistry, 2022
- Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein–Protein InteractionJournal of Medicinal Chemistry, 2021
- Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein–Protein InteractionJournal of Medicinal Chemistry, 2021
- WNT/β-catenin signaling in the development of liver cancersBiomedicine & Pharmacotherapy, 2020
- The coming of age of de novo protein designNature, 2016
- Wnt signaling in cancerOncogene, 2016
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Crystal Structure of a β-Catenin/BCL9/Tcf4 ComplexMolecular Cell, 2006
- Wnt signalling in stem cells and cancerNature, 2005
- Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator functionNature Cell Biology, 2004